Cochrane Review Group
Multiple Sclerosis and Rare Diseases of the CNS
37 systematic reviews in Multiple Sclerosis and Rare Diseases of the CNS ask 448 questions. 11.2% have no studies to answer them, 29.5% rest on very low certainty evidence and 20.6% reach moderate or high certainty.
Reviews
37
Questions
448
current versions
No studies
11.2%
Moderate or high
20.6%
No studies 50 · 11.2%Ungraded 14 · 3.1%Very low 132 · 29.5%Low 160 · 35.7%Moderate 76 · 17%High 16 · 3.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | RR 0.77 [0.51, 1.18] | 1 study · 59 participants | Very low |
Intervention NR Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | RR 0.91 [0.58, 1.43] | 1 study · 59 participants | Very low |
Intervention NR Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | RR 1.21 [0.66, 2.19] | 1 participants | Very low |
Intervention NR Teriflunomide (Direct evidence; 1 RCT; 1088 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | RR 0.82 [0.71, 0.94] | 1 study · 1088 participants | Very low |
Intervention NR Placebo · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403 participants) Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | RR 0.86 [0.67, 1.11] | 1 study · 2 participants | Very low |
Intervention NR Placebo Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies and participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 37
Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
CochraneSoF table
94 questions
Alemtuzumab for multiple sclerosis
CochraneSoF table
12 questions
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis
CochraneSoF table
40 questions
Ocrelizumab for multiple sclerosis
CochraneSoF table
13 questions
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
CochraneSoF table
9 questions
Memory rehabilitation for people with multiple sclerosis
CochraneSoF table
7 questions
Siponimod for multiple sclerosis
CochraneSoF table
7 questions
Rituximab for people with multiple sclerosis
CochraneSoF table
27 questions
Dietary interventions for multiple sclerosis‐related outcomes
CochraneSoF table
15 questions
Ventriculo‐peritoneal shunting devices for hydrocephalus
CochraneSoF table
20 questions
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis
CochraneSoF table
3 questions
Interventions for preventing falls in people with multiple sclerosis
CochraneSoF table
4 questions
Route of antibiotic prophylaxis for prevention of cerebrospinal fluid‐shunt infection
CochraneSoF table
4 questions
Palliative care interventions for people with multiple sclerosis
CochraneSoF table
7 questions
Vitamin D for the management of multiple sclerosis
CochraneSoF table
5 questions
Information provision for people with multiple sclerosis
CochraneSoF table
5 questions
Non‐pharmacological interventions for chronic pain in multiple sclerosis
CochraneSoF table
28 questions
Respiratory muscle training for multiple sclerosis
CochraneSoF table
6 questions
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
CochraneSoF table
13 questions
Intravenous immunoglobulin for the treatment of childhood encephalitis
CochraneSoF table
3 questions
Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
CochraneSoF table
6 questions
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
CochraneSoF table
7 questions
Fingolimod for relapsing‐remitting multiple sclerosis
CochraneSoF table
12 questions
Teriflunomide for multiple sclerosis
CochraneSoF table
7 questions
Exercise therapy for fatigue in multiple sclerosis
CochraneSoF table
11 questions